SAMe Trial for Patients With Alcoholic Cirrhosis
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Alcoholic Cirrhosis
In brief
The proposed of this randomized, double blinded, placebo-controlled study is to assess the effect of SAMe compared to placebo in patients with alcoholic cirrhosis Child Class A and B. The primary objective of the study is to test relationship between SAMe (S-adenosylmethionine) supplement on liver function. The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.
Key facts
- Study ID
- NCT04250259
- Run by
- Indiana University
- People needed
- 196
- Starts
- 2020-10-22
- Expected to finish
- 2027-03-01
- Last updated by the study team
- 2026-03-31
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
Where it is running
- Cedars-Sinai Medical Center — Los Angeles, California, United States (enrolling)
- Indiana University Hospital — Indianapolis, Indiana, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.